Daily Testing at Home by NV-AMD Subjects With Notal Home OCT.

Completed

Conditions studied: Retinal Neovascularization

In brief

The purpose of this study is to evaluate the ability of subjects with NV-AMD to perform sequential daily self-imaging of their eyes with the self-operated Notal Home OCT device in their homes for 90 days without on-site supervision. The study will include up to 15 subjects.

Key facts

Study ID

NCT04650672

Run by

Notal Vision Inc.

People needed

15

Starts

2020-12-08

Expected to finish

2021-09-30

Last updated by the study team

2021-11-29

Who can join

Age: 55 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ability to speak and understand English with fluency.
• Ability to understand and agree to contents of informed consent either in writing or verbally.
• At least 55 years of age on date of Screening Visit.
• Diagnosed with NV-AMD in at least one eye and initiation of anti-VEGF treatment in that eye.
• At least one enrolled eye per subject had retinal fluid treated with anti-VEGF in the prior 6 months, with a treatment interval of 8 weeks or less.
• Visual Acuity of 20/320 or better.
• Available and willing to conduct daily self-imaging at home for the duration of the trial.

You may not qualify if…

• Any other retinal disease in the study eye requiring steroidal or anti-VEGF injections (anti-VEGF injections during the study period must be for NV-AMD).
• Subject's schedule not conducive to completing daily tests at home with the Notal Home OCT device for the duration of the study.

Where it is running

• Ophthalmic Cons. of Boston — Boston, Massachusetts, United States
• Pepose Vision Institute — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.